---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-016548"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-04-29T23:59:59+00:00"
generated_at: "2026-06-26T02:30:46.020912+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma stockholders approve doubling authorized shares to 85M

## Summary
- Stockholders approved increase in authorized common shares from 42.5M to 85,000,000.
- Amendment to 2015 Stock Plan approved, increasing reserved shares by 2,000,000.
- Amendment to 2015 ESPP approved, increasing reserved shares by 750,000 and per-employee limit to 2,500.
- All three Class I director nominees elected (John Clarke, Paul Schimmel, Sara Zaknoen).
- Ratification of Ernst & Young as auditor and advisory approval of executive compensation.

## SEC filing metadata
- accession: 0001564590-22-016548
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459022016548/0001564590-22-016548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459022016548/life-8k_20220426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-016548
- JSON: https://secwatch.observer/filing/0001564590-22-016548.json
- Plain text: https://secwatch.observer/filing/0001564590-22-016548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.